Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-5 (of 5 Records) |
Query Trace: Wilner L[original query] |
---|
Effective delivery of social and behavior change communication through a Care Group model in a supplementary feeding program
Wilner L , Suri DJ , Langlois BK , Walton SM , Rogers BL . J Health Popul Nutr 2017 36 (1) 34 BACKGROUND: In 2014, an intervention aimed at increasing the oil in corn soy blend (CSB) porridge prepared by caregivers of children with moderate acute malnutrition was implemented in Southern Malawi. This analysis describes the flow of key messages delivered through the Care Group model during this intervention. METHODS: The intervention provided a supplementary food ration of CSB and oil and used a Care Group model in which healthcare workers were trained to deliver social and behavior change communication (SBCC) to care group volunteers who then delivered messages to caregivers of beneficiary children. Healthcare workers also delivered messages to caregivers directly. Interviews and focus groups were conducted with all three groups in order to determine the exchange of key messages about ingredient use, storage, and purpose, which were analyzed descriptively. RESULTS: Analysis of SBCC flow and information exchange showed that 100% of caregivers reported learning about the amounts of oil and CSB to use while preparing porridge and over 90% of caregivers, healthcare workers, and care group volunteers reported talking about it. Focus groups confirmed an effective flow of communication among these three groups. CONCLUSION: This analysis evaluated the flow of key SBCC messages through multiple, overlapping lines of communication among healthcare workers, care group volunteers, and caregivers; the effective transmission of these SBCC messages through this model may contribute to the success of a supplementary feeding intervention program. TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov ( NCT01873196 ). |
Sustained use in a relief-to-recovery household water chlorination program in Haiti: Comparing external evaluation findings with internal supervisor and community health worker monitoring data
Wilner L , Wells E , Ritter M , Casimir JM , Chui K , Lantagne D . J Water Sanit Hyg Dev 2017 7 (1) 56-66 After the January 2010 earthquake in Haiti, an existing development program promoting household water treatment with chlorine rapidly expanded and provided relief to 15,000 earthquake-affected households. Initially, 157 community health workers (CHWs) distributed chlorine tablets; ten months later, CHWs began selling locally manufactured solution. The program was externally evaluated in March and November 2010; 77–90% of recipients had free chlorine residual (FCR) in household water. Internal monitoring by three supervisors and 157 CHWs also began in 2010. We analyzed results from 9,832 supervisor and 80,371 CHW monitoring visits conducted between 2010 and 2014 to assess: whether success continued in the rehabilitation phase; internal data validity; and factors impacting adoption. In 2010, 72.7% of supervisor visits documented total chlorine residual (TCR) comparable to external evaluation results. TCR presence was associated with certain supervisors/ CHWs, earlier program year and month (in 2014, supervisor visits TCR presence dropped to 52.1%), living in plains (not mountainous) regions, and certain calendar months. CHW visits recorded 18.1% higher TCR presence than supervisor visits, indicating bias. Our results document a program with sustained (although slightly declining) household chlorination use, provide insight into validity in internal monitoring, and inform discussions on the value of linking successful development programs to emergency relief, rehabilitation, and development. |
Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society
Harden CL , Hopp J , Ting TY , Pennell PB , French JA , Hauser WA , Wiebe S , Gronseth GS , Thurman D , Meador KJ , Koppel BS , Kaplan PW , Robinson JN , Gidal B , Hovinga CA , Wilner AN , Vazquez B , Holmes L , Krumholz A , Finnell R , Le Guen C , American Academy of Neurology American Epilepsy Society . Neurology 2009 73 (2) 126-32 OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including the risk of pregnancy complications or other medical problems during pregnancy in WWE compared to other women, change in seizure frequency, the risk of status epilepticus, and the rate of remaining seizure-free during pregnancy. METHODS: A 20-member committee including general neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review and classification of relevant articles published between 1985 and February 2008. RESULTS: For WWE taking antiepileptic drugs, there is probably no substantially increased risk (greater than two times expected) of cesarean delivery or late pregnancy bleeding, and probably no moderately increased risk (greater than 1.5 times expected) of premature contractions or premature labor and delivery. There is possibly a substantially increased risk of premature contractions and premature labor and delivery during pregnancy for WWE who smoke. Seizure freedom for at least 9 months prior to pregnancy is probably associated with a high likelihood (84%-92%) of remaining seizure-free during pregnancy. RECOMMENDATIONS: Women with epilepsy (WWE) should be counseled that seizure freedom for at least 9 months prior to pregnancy is probably associated with a high rate (84%-92%) of remaining seizure-free during pregnancy (Level B). However, WWE who smoke should be counseled that they possibly have a substantially increased risk of premature contractions and premature labor and delivery during pregnancy (Level C). |
Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society
Harden CL , Meador KJ , Pennell PB , Hauser WA , Gronseth GS , French JA , Wiebe S , Thurman D , Koppel BS , Kaplan PW , Robinson JN , Hopp J , Ting TY , Gidal B , Hovinga CA , Wilner AN , Vazquez B , Holmes L , Krumholz A , Finnell R , Hirtz D , Le Guen C , American Academy of Neurology American Epilepsy Society . Neurology 2009 73 (2) 133-41 OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. METHODS: Systematic review of relevant articles published between January 1985 and June 2007. RESULTS: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of <7. RECOMMENDATIONS: If possible, avoidance of valproate (VPA) and antiepileptic drug (AED) polytherapy during the first trimester of pregnancy should be considered to decrease the risk of major congenital malformations (Level B). If possible, avoidance of VPA and AED polytherapy throughout pregnancy should be considered to prevent reduced cognitive outcomes (Level B). If possible, avoidance of phenytoin and phenobarbital during pregnancy may be considered to prevent reduced cognitive outcomes (Level C). Pregnancy risk stratification should reflect that the offspring of women with epilepsy taking AEDs are probably at increased risk for being small for gestational age (Level B) and possibly at increased risk of 1-minute Apgar scores of <7 (Level C). |
Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society
Harden CL , Pennell PB , Koppel BS , Hovinga CA , Gidal B , Meador KJ , Hopp J , Ting TY , Hauser WA , Thurman D , Kaplan PW , Robinson JN , French JA , Wiebe S , Wilner AN , Vazquez B , Holmes L , Krumholz A , Finnell R , Shafer PO , Le Guen C , American Academy of Neurology American Epilepsy Society . Neurology 2009 73 (2) 142-9 OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folic acid use, prenatal vitamin K use, risk of hemorrhagic disease of the newborn, clinical implications of placental and breast milk transfer of antiepileptic drugs (AEDs), risks of breastfeeding, and change in AED levels during pregnancy. METHODS: A 20-member committee evaluated the available evidence based on a structured literature review and classification of relevant articles published between 1985 and October 2007. RESULTS: Preconceptional folic acid supplementation is possibly effective in preventing major congenital malformations in the newborns of WWE taking AEDs. There is inadequate evidence to determine if the newborns of WWE taking AEDs have a substantially increased risk of hemorrhagic complications. Primidone and levetiracetam probably transfer into breast milk in amounts that may be clinically important. Valproate, phenobarbital, phenytoin, and carbamazepine probably are not transferred into breast milk in clinically important amounts. Pregnancy probably causes an increase in the clearance and a decrease in the concentration of lamotrigine, phenytoin, and to a lesser extent carbamazepine, and possibly decreases the level of levetiracetam and the active oxcarbazepine metabolite, the monohydroxy derivative. RECOMMENDATIONS: Supplementing women with epilepsy with at least 0.4 mg of folic acid before they become pregnant may be considered (Level C). Monitoring of lamotrigine, carbamazepine, and phenytoin levels during pregnancy should be considered (Level B) and monitoring of levetiracetam and oxcarbazepine (as monohydroxy derivative) levels may be considered (Level C). A paucity of evidence limited the strength of many recommendations. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure